DTIL
Precision BioSciences, Inc. NASDAQ$7.63
Mkt Cap $97.9M
52w Low $3.53
77.5% of range
52w High $8.82
50d MA $6.05
200d MA $5.28
P/E (TTM)
-2.0x
EV/EBITDA
0.6x
P/B
1.0x
Debt/Equity
0.3x
ROE
-49.6%
P/FCF
-0.8x
RSI (14)
—
ATR (14)
—
Beta
1.09
50d MA
$6.05
200d MA
$5.28
Avg Volume
270.4K
About
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to reco…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 12, 2026 | BMO | -0.21 | 0.36 | +271.4% | 5.67 | +1.8% | +0.0% | +0.0% | +11.1% | +22.2% | +24.0% | — |
| Nov 3, 2025 | BMO | -0.31 | -1.84 | -493.5% | 7.36 | -1.5% | -9.1% | -9.1% | -10.1% | -12.5% | -16.6% | — |
| Aug 7, 2025 | BMO | -0.09 | -2.13 | -2266.7% | 4.57 | -0.9% | -4.2% | -4.2% | -4.8% | -4.2% | +2.6% | — |
| May 15, 2025 | BMO | -0.43 | -2.21 | -414.0% | 4.55 | +2.0% | +3.5% | +3.5% | +3.1% | +7.3% | +2.2% | — |
| Mar 26, 2025 | BMO | -2.09 | -3.20 | -53.1% | 4.53 | +2.9% | +0.2% | +0.2% | +3.8% | +5.3% | -0.9% | — |
| Nov 4, 2024 | BMO | -0.79 | -2.83 | -258.2% | 8.29 | -1.6% | +2.1% | +2.1% | +1.3% | +1.6% | +1.1% | — |
| Aug 1, 2024 | BMO | -0.77 | 3.46 | +549.4% | 9.57 | +0.6% | -2.6% | -2.6% | -6.9% | -9.1% | -10.2% | — |
| May 13, 2024 | BMO | -0.45 | -0.35 | +22.2% | 11.50 | +4.3% | +1.0% | +1.0% | +5.1% | +4.2% | +7.8% | — |
| Mar 27, 2024 | BMO | 3.00 | -3.35 | -211.7% | 12.98 | +2.0% | +4.5% | +4.5% | +18.4% | +9.4% | +19.0% | — |
| Nov 7, 2023 | BMO | -5.71 | -3.00 | +47.5% | 11.70 | +2.6% | +0.8% | +0.8% | +1.0% | -2.8% | -12.1% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.88 | $4.85 | -0.6% | -4.7% | -4.9% | -6.1% | +0.2% | +1.8% |
| Mar 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.54 | $4.75 | +4.6% | +3.5% | +5.1% | -1.1% | +3.3% | +3.7% |
| Mar 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.98 | $4.95 | -0.6% | +0.6% | +7.6% | +9.4% | +13.3% | +2.2% |
| Feb 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.15 | $5.35 | +3.9% | +9.7% | +14.4% | +15.1% | +9.3% | +6.2% |
| Jan 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.50 | $6.80 | +51.1% | +26.7% | +27.6% | +19.6% | +16.9% | +4.9% |
| Jan 10 | BMO Capital | Upgrade | Market Perform → Outperform | — | $4.50 | $6.80 | +51.1% | +26.7% | +27.6% | +19.6% | +16.9% | +4.9% |
| May 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.27 | $12.15 | -1.0% | +4.5% | +5.1% | +6.8% | +7.8% | +6.0% |
| May 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.09 | $12.12 | +0.2% | -0.9% | +2.6% | +6.2% | +7.9% | +8.2% |
| Apr 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.87 | $11.79 | -8.4% | -10.6% | -16.7% | -24.3% | -24.8% | -20.5% |
| Mar 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.98 | $13.24 | +2.0% | +4.5% | +18.4% | +9.4% | +19.0% | +10.5% |
Recent Filings
8-K · 2.02
!! High
Precision BioSciences, Inc. -- 8-K 2.02: Earnings Results
Precision BioSciences reported earnings results through a press release filed as an exhibit, with detailed financial performance information available in the full disclosure document for investor review.
May 5
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
DTIL presented Duchenne muscular dystrophy gene therapy data to key opinion leaders, signaling clinical progress that could validate its pipeline and drive future revenue potential.
Mar 17
8-K
Unknown — 8-K Filing
Precision BioSciences (DTIL) executed its 2025 pipeline milestones, suggesting operational competence, but as a clinical-stage biotech with no revenue, investors face binary trial risk before profitability materializes.
Mar 12
8-K · 8.01
!! High
Precision BioSciences, Inc. -- 8-K 8.01: Material Event / Announcement
Precision BioSciences received FDA clearance to proceed with its FUNCTION-DMD Phase 1/2 clinical trial, allowing the company to activate U.S. clinical sites for its gene therapy treatment.
Feb 11
Data updated apr 25, 2026 5:57am
· Source: massive.com